Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease |
| |
| Authors: | Davide Capodanno Alessio La Manna Maria Elena Di Salvo Alessandra Sanfilippo Thierry Corcos Corrado Tamburino |
| |
| Affiliation: | 1. Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany;2. Herzzentrum Segeberger Kliniken GmbH, Bad Segeberg, Germany;3. Instituto do Coração – HCFMUSP, University of Sao Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, Brazil;4. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark;5. INCOR - University of Sao Paulo, Sao Paulo, Brazil;6. Department of Cardiology, Medisch Spectrum Twente, Thoraxcentrum Twente, Enschede, the Netherlands;7. Klinik für Kardiologie und Angiologie II, Universitäts-Herzzentrum Freiburg, Bad Krozingen, Germany;8. The Lambe Institute for Translational Medicine, the Smart Sensors Laboratory and Curam, National University of Ireland Galway (NUIG), Galway, Ireland;9. Department of Cardiology, Vivantes Klinikum im Friedrichshain and Am Urban, Berlin, Germany;10. Department of Cardiology, Rostock University Medical Center, Rostock, Germany;11. Klinik für Kardiologie, Universitätsspital Basel, Basel, Switzerland;12. National Heart Centre Singapore, Singapore;13. Hospital Clinico San Carlos IDISSC, Complutense University of Madrid, Madrid, Spain;14. CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;15. Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA |
| |
| Abstract: | BackgroundThe potential for the CATANIA (CAT) stent to be an alternative to both bare-metal stents (BMS) and drug-eluting stents (DES) has been recently demonstrated in the Assessment of The LAtest Non-Thrombogenic Angioplasty stent (ATLANTA) first-in-human study. The aim of the present study was to compare short-term outcomes of patients treated with the CAT stent with those treated with BMS.MethodsBased on an internal registry, the 30-day and 6-month risk-adjusted outcomes for patients who received the CAT stent (n=254) were compared against outcomes of a historical cohort of patients who received BMS (n=552) between January 2001 and December 2001.ResultsAt 30 days, use of BMS vs. the CAT stent resulted in borderline significant differences with respect to major adverse cardiac and cerebrovascular events (MACCE) and cardiac death or myocardial infarction. At 6 months, BMS showed a statistically significant higher adjusted risk of MACCE (HR 2.79, 95% CIs 1.20–6.48, P=.017) and no differences with respect to the subcomponent end points. The cumulative incidence of definite stent thrombosis (Academic Research Consortium defined) at 6 months was 0.39% for the CAT stent and 2.35% for the BMS.ConclusionsThis study confirms the favorable early and mid-term safety profile and the high-level efficacy of the CAT stent in the treatment of de novo coronary lesions seen in the ATLANTA trial. The use of stents with a nanothin Polyzene-F surface treatment provided improved results with respect to BMS and lower risk of acute and subacute stent thrombosis. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
